Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
49.11
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
46
47
Next >
3 Fast-Growing Medical Dividend Stocks
October 17, 2022
Sometimes, the strongest payout growth can be found among the future Dividend Aristocrats, not the current ones.
Via
The Motley Fool
Peering Into Bristol-Myers Squibb's Recent Short Interest
October 13, 2022
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 4.63% since its last report. The company recently reported that it has 24.18 million shares sold short, which is 1.13% of all regular...
Via
Benzinga
Got $5,000? These 2 Stocks Could Continue Beating the Bear Market.
October 12, 2022
These two stocks have solid fundamentals and are delivering strong results.
Via
The Motley Fool
The 7 Most Undervalued Value Stocks to Buy Now
October 10, 2022
Undervalued value stocks remain available even as investors have pivoted toward low-valuation stocks in a volatile year for markets.
Via
InvestorPlace
What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb
October 10, 2022
Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings:
Via
Benzinga
Will Chart Analysts Notice Bad Omen on Bristol-Myers Squibb's Chart
October 10, 2022
If history is any guide, there may be trouble ahead for shares of Bristol-Myers Squibb (NYSE:BMY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the...
Via
Benzinga
Bristol Myers Squibb Company: Too Cheap To Ignore
October 07, 2022
Since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well.
Via
Talk Markets
Bristol Myers' Opdivo Combo Treatment Scores European Approval For Skin Cancer Setting
September 19, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
October 10, 2022
Upgrades
Via
Benzinga
Want to Buy the Dip? This Real Estate Stock Is a Smart Buy
October 07, 2022
This REIT specializes in office space for white-coat lab work that can't really be done at home.
Via
The Motley Fool
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
October 07, 2022
Via
Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
October 06, 2022
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera
Via
Benzinga
3 Stocks Savvy Investors Are Buying Hand Over Fist
October 06, 2022
These high-flying stocks are defying the bear market.
Via
The Motley Fool
Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner
October 05, 2022
There's a reason BMY stock is currently winning our Best Stocks for 2022 contest. Investors should buy BMY for value, safety and dividends.
Via
InvestorPlace
Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4
October 04, 2022
While Sonic Automotive isn’t in the lead for the top 10 best stocks ranking, SAH stock performs relatively well because of its fundamentals.
Via
InvestorPlace
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
October 04, 2022
Via
Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock
September 23, 2022
The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades
September 23, 2022
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY) has a “good dividend yield” and is a &l
Via
Benzinga
Salesforce Is Among Thursday's CNBC 'Fast Money' Final Trades
September 22, 2022
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined...
Via
Benzinga
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
September 22, 2022
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell...
Via
Benzinga
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
September 20, 2022
Joe Biden’s cancer moonshot gave some of the drug companies a big shot in the arm. These three stocks all are doing big things in oncology.
Via
InvestorPlace
What Are Whales Doing With Bristol-Myers Squibb
September 19, 2022
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Amazon, Target And 3 Other Stocks Insiders Are Selling
September 19, 2022
U.S. crude oil futures traded lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
7 Penny Stocks That Actually Have a Buy Rating
September 19, 2022
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.
Via
InvestorPlace
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%
September 19, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording losses on Friday. All the three major indices recorded losses last week, with the Dow Jones dropping...
Via
Benzinga
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday
September 19, 2022
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
September 16, 2022
Via
Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
September 16, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 10 strange trades.
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.